Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

is trading on a 6.8x 2015E projected earnings per share multiple[9]. The Proposal Price represents 30.6x Elan's 2015E Broker Projected Earnings Per Share. Were the Valeant or Jazz multiples referenced above to be applied to Elan's 2015E Broker Projected Earnings Per Share, they would imply a share price of US$3.15 and US$2.44 respectively. Equally, if the Proposal Price were divided by the Valeant or Jazz multiples referenced above respectively, the resulting implied earnings per share would be US$1.26 or US$1.62 respectively, both materially higher than Elan's 2015E Broker Projected Earnings Per Share of US$0.36.

Were Elan to distribute its net cash and the share price declined proportionally, the implied 2015E earnings per share multiple at the Proposal Price would be 16.7x[10], still materially above the corresponding multiples of Jazz or Valeant.

Elan management's strategy and the risks associated with itRoyalty Pharma believes that there are a number of significant risks associated with Elan's new business plan, many of which were identified in the Proposal Announcement. In particular, Royalty Pharma believes that each new investment made by Elan will be scrutinized to ascertain near-term value creation potential, thereby increasing the volatility in Elan Stock.

Royalty Pharma believes that these risks were demonstrated by Elan's February 6, 2013 announcement of the Tysabri Transaction, as well as by the change of heart evident in Elan's recent statements, following the receipt of Royalty Pharma's Proposal.

The day of the announcement of the Tysabri Transaction

On February 6, 2013, the day of the announcement of the Tysabri Transaction, Royalty Pharma believes that Elan revealed its true colors during the Tysabri Conference Call[11].

Elan stated that it would use "a majority of" the Tysabri Consideration for acquisitions in statements which Royalty Pharma believes were unclear and unfocused. Elan's statements
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
(Date:10/18/2014)... October 19, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers, restraints, challenges, opportunities, current market trends, and ... with the estimates and forecasts of the revenue ...
(Date:10/18/2014)... Asia-Pacific Liquid Crystal on Silicon (LCoS) display market report ... analysis and forecast of revenue. This market was valued ... reach $380.0 million by 2018, at a CAGR of ... TOC of the Asia-Pacific LCoS display market report, to ... also provides a glimpse of the segmentation of the ...
(Date:10/18/2014)... 2014 The “Global Diagnostic Electrocardiograph ... by End-user (Hospitals, Home/Ambulatory, Research Center, Physician Office, ... -Global Forecast to 2020” provides a detailed overview ... market trends, and strategies impacting the global diagnostic ... of the revenue and share analysis. , The ...
Breaking Biology Technology:The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5
... LA JOLLA, Calif., March 18 TorreyPines Therapeutics,Inc. ... initiated a Phase II study of,NGX267, a muscarinic ... to Sjogren,s syndrome., The company is conducting ... square design to evaluate,the safety, tolerability and efficacy ...
... NEOG ) announces the following Webcast:, What: Neogen ... EDT, Where: http://www.videonewswire.com/event.asp?id=46587 , How: ... the address above., ... are unable to participate during the live webcast, the call will,be archived ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,344,711 entitled "Use of Adenoviruses Mutated in the,VA ... of treating,cancer using adenoviruses that are modified to ... Ras pathway., "This patent expands our adenovirus ...
Cached Biology Technology:TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... nutrient world The budding yeast, Saccharomyces ... cellular processes, with the functions of many proteins important ... human biology having first been discovered in yeast. ... developed a sophisticated assay to track cell growth at ...
... 17, 2013) The New York Genome Center (NYGC) ... (NYSCF) has become an Associate Member, joining NYGC,s growing ... together in new ways to utilize genomic data for ... at the NYSCF working with the genomic scientists at ...
... From Promise to Practice is the title and the ... at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more ... in Minnesota to hear and learn about the latest ... move these discoveries into the medical practice. "Our ...
Cached Biology News:Recent highlights in Molecular Biology and Evolution 2Recent highlights in Molecular Biology and Evolution 3New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 2New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 3Mayo Clinic hosts NIH genomics director at Individualizing Medicine Conference 2
Recombinant Equine IL-6...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
Biology Products: